Get the Stockscreener App
18.97
4.39%
-0.87
After Hours:
18.97
Zenas Biopharma Inc stock is traded at $18.97, with a volume of 342.23K.
It is down -4.39% in the last 24 hours and down -5.48% over the past month.
Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. The Company manages its operations on a consolidated basis as a single reportable segment focused on the research, development and commercialization of transformative immunology-based therapies.
See More
Previous Close:
$19.84
Open:
$19.99
24h Volume:
342.23K
Relative Volume:
0.49
Market Cap:
$1.20B
Revenue:
$10.00M
Net Income/Loss:
$-377.74M
P/E Ratio:
-2.2467
EPS:
-8.4436
Net Cash Flow:
$-172.35M
1W Performance:
+3.44%
1M Performance:
-5.48%
6M Performance:
-47.01%
1Y Performance:
+65.68%
1-Day Range:
$18.94
$20.16
1-Week Range:
$16.41
$20.19
52-Week Range:
$8.91
$44.60
Zenas Biopharma Inc Stock (ZBIO) Company Profile
Name
Zenas Biopharma Inc
Sector
Industry
Phone
857-271-2954
Address
852 WINTER STREET, SUITE 250, WALTHAM
Compare ZBIO vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ZBIO
Zenas Biopharma Inc
|
18.97 | 1.25B | 10.00M | -377.74M | -172.35M | -8.4436 |
VRTX
Vertex Pharmaceuticals Inc
|
434.52 | 110.03B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
638.88 | 67.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.46 | 50.76B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.45 | 40.12B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
151.56 | 32.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Zenas Biopharma Inc Stock (ZBIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-05-26 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Mar-20-25 | Initiated | Wedbush | Outperform |
| Feb-04-25 | Initiated | Wolfe Research | Outperform |
| Dec-16-24 | Initiated | H.C. Wainwright | Buy |
| Nov-05-24 | Initiated | Rodman & Renshaw | Buy |
| Oct-08-24 | Initiated | Citigroup | Buy |
| Oct-08-24 | Initiated | Guggenheim | Buy |
| Oct-08-24 | Initiated | Jefferies | Buy |
| Oct-08-24 | Initiated | Morgan Stanley | Overweight |
View All
Zenas Biopharma Inc Stock (ZBIO) Latest News
What Zenas BioPharma (ZBIO)'s First-in-Human Oral IL-17 Inhibitor Trial Means For Shareholders - Sahm
ZBIO INVESTOR ALERT: Zenas BioPharma, Inc. Investors with Substa - GuruFocus
Zenas BioPharma to present obexelimab trial data at EULAR congress - Investing.com UK
Zenas BioPharma to present obexelimab trial data at EULAR congress By Investing.com - Investing.com Nigeria
Why is Zenas Biopharma stock climbing today? By Investing.com - Investing.com Australia
Zenas BioPharma To Present INDIGO Phase 3 Data At EULAR 2026; Wedbush Sees $45 Target - RTTNews
Zenas BioPharma Announces Upcoming Presentation of Results from Phase 3 INDIGO Registrational Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD) at EULAR 2026 Congress - The Manila Times
Obexelimab cuts IgG4-RD flare risk 56%, results to be presented at EULAR 2026 - Stock Titan
Zenas BioPharma Insider Bought Shares Worth $1,012,800, According to a Recent SEC Filing - Moomoo
Zenas BioPharma CEO Leon Moulder Jr purchases $1.01m in common stock By Investing.com - Investing.com South Africa
Zenas BioPharma CEO Leon Moulder Jr purchases $1.01m in common stock - Investing.com Australia
Zenas BioPharma (ZBIO) CEO adds 60,000 shares in open-market buy - Stock Titan
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Zenas BioPharma Advances Phase 3 Orelabrutinib Trial in Tough MS Segment - TipRanks
Zenas BioPharma rises as CEO continues insider purchases - MSN
Assessing Zenas BioPharma (ZBIO) Valuation After Obexelimab Phase 3 Success And New IL-17 Program Progress - Sahm
Vanguard Group Inc. Acquires 290,307 Shares of Zenas BioPharma, Inc. $ZBIO - MarketBeat
ZBIO Reiterated by HC Wainwright & Co. -- Price Target Maintained at $44 - GuruFocus
H.C. Wainwright Maintains Zenas BioPharma(ZBIO.US) With Buy Rating, Maintains Target Price $44 - Moomoo
Citi opens ‘upside 30-day catalyst watch’ on Zenas BioPharma - TipRanks
symbol__ Stock Quote Price and Forecast - CNN
Morgan Stanley Maintains Zenas BioPharma(ZBIO.US) With Hold Rating, Raises Target Price to $22 - Moomoo
How Zenas BioPharma’s First-in-Human Oral IL-17 Trial Could Reframe Zenas BioPharma (ZBIO) Investors - Sahm
ZBIO SWOT Analysis: Financial Challenges and Growth Potential Re - GuruFocus
Zenas BioPharma Releases Q1 2026 Financial Results - AlphaStreet
Why Zenas BioPharma (ZBIO) Is Down 7.7% After Reporting a Sharply Wider Quarterly Net Loss - Yahoo Finance
Zenas BioPharma 4Q Loss/Shr $1.46 >ZBIO - Moomoo
Zenas BioPharma, Inc. 2026 Q1 Financial Report: Forward-Looking Statements, Risk Factors, and Management Discussion - Minichart
Zenas BioPharma doses first patient in Phase 1 clinical trial of ZB021 - TipRanks
Zenas BioPharma doses first patient in ZB021 phase 1 trial By Investing.com - Investing.com Nigeria
Zenas BioPharma doses first patient in ZB021 phase 1 trial - Investing.com
Zenas BioPharma Reports Q1 2026 Results: Obexelimab Nears FDA Submission for IgG4-RD, Pipeline Advances, and Cash Runway Extended to 2029 1245 - Minichart
Zenas BioPharma Announces First Subject Dosed in Phase 1 Clinical Trial of ZB021, a Novel, Potentially Best-in-Class Oral IL-17AA/AF Inhibitor - The Manila Times
Zenas Biopharma Announces First Subject Dosed In Phase 1 Clinical Trial Of Zb021, A Novel, Potentially Best-In-Class Oral Il-17Aa/Af Inhibitor - TradingView
Zenas BioPharma (Nasdaq: ZBIO) doubles cash while quarterly loss widens - Stock Titan
Zenas BioPharma reports Q1 EPS ($1.46) vs. (80c) last year - TipRanks
Zenas BioPharma Highlights Strong Q1 Progress and Financing - TipRanks
Zenas BioPharma, Inc. 1Q 2026: Revenue $16.91M, EPS ($1.46) — 10-Q Summary - TradingView
Zenas BioPharma (NASDAQ: ZBIO) widens loss but lifts cash to $718.5M - Stock Titan
Tomas Kiselak resigns from Zenas BioPharma board after term expiration - TradingView
Zenas BioPharma Q1 Net Loss Widens - Moomoo
Zenas BioPharma Reports First Quarter 2026 Financial Results and Provides Corporate Update - The Manila Times
Earnings Flash (ZBIO) Zenas BioPharma Posts Q1 Net Loss $1.46 a Share, vs. FactSet Est of $1.47 Loss - marketscreener.com
Zenas BioPharma Reports Progress on Obexelimab and ZB021 Trials, Financial Milestones and Upcoming Regulatory Submissions - Quiver Quantitative
Earnings Flash (ZBIO) Zenas BioPharma Posts Q1 Net Loss $1.46 a Share, Vs. FactSet Est of $1.47 Loss - Moomoo
TradingKey - TradingKey
Number of shareholders of Zenas BioPharma, Inc. – NASDAQ:ZBIO - TradingView
Alpha Buying: Insider Conviction in High-Risk Biotech - Sahm
Zenas BioPharma (ZBIO) CEO and entities report 3,220,880 shares owned - Stock Titan
Zenas Biopharma Inc Stock (ZBIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.98%
1.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):